Bangor – Acadia Hospital was recently recognized for outstanding contributions to the NOBLE study, a Phase 2 clinical study of a drug called T-817 that may slow progression of Alzheimer’s disease.
Acadia partners with EMMC’s Clinical Research Center to provide grant and research support.
In consultation with family caregivers, Acadia Hospital is now seeking eligible candidates for NOBLE. To be eligible to participate, people must be between 55 and 85 with mild-to-moderate Alzheimer’s disease, and have been taking certain Alzheimer’s medications for at least four months. For additional information on the NOBLE study, please visit: www.NOBLEstudy.org or contact Claudine Allen, RN at the EMMC Clinical Research Center 207-973-9013.